Dr. Daniel Bowles, MD
Claim this profileUniversity of Colorado Hospital
Area of expertise
Salivary Gland Cancer
Daniel Bowles, MD has run 3 trials for Salivary Gland Cancer. Some of their research focus areas include:
Salivary Gland Carcinoma
Daniel Bowles, MD has run 2 trials for Salivary Gland Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
University Of Colorado Hospital
UCHealth University Of Colorado Hospital
Clinical Trials Daniel Bowles, MD is currently running
High Dose Testosterone
for Prostate Cancer
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Recruiting
3 awards
Phase 2
Trastuzumab Emtansine
for Salivary Gland Cancer
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where it first started (primary site) to other places in the body, or cannot be removed by surgery (unresectable). This trial is also testing how well trastuzumab deruxtecan works in treating patients with HER2-low recurrent or metastatic salivary gland cancer. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by body's immune system. Trastuzumab emtansine contains trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab deruxtecan is a monoclonal antibody called traztuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors and delivers deruxtecan to kill them. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab or trastuzumab deruxtecan in treating patients with recurrent, metastatic or unresectable salivary gland cancer.
Recruiting
1 award
Phase 2
More about Daniel Bowles, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Daniel Bowles, MD has experience with
- Atezolizumab
- Stereotactic Body Radiation Therapy
- Docetaxel
- Trastuzumab
- Trastuzumab Emtansine
- Darolutamide
Breakdown of trials Daniel Bowles, MD has run
Salivary Gland Cancer
Salivary Gland Carcinoma
Prostate Cancer
Adenoid Cystic Carcinoma
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Bowles, MD specialize in?
Daniel Bowles, MD focuses on Salivary Gland Cancer and Salivary Gland Carcinoma. In particular, much of their work with Salivary Gland Cancer has involved Stage IV patients, or patients who are Stage III.
Is Daniel Bowles, MD currently recruiting for clinical trials?
Yes, Daniel Bowles, MD is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Daniel Bowles, MD has studied deeply?
Yes, Daniel Bowles, MD has studied treatments such as Atezolizumab, Stereotactic Body Radiation Therapy, Docetaxel.
What is the best way to schedule an appointment with Daniel Bowles, MD?
Apply for one of the trials that Daniel Bowles, MD is conducting.
What is the office address of Daniel Bowles, MD?
The office of Daniel Bowles, MD is located at: University of Colorado Hospital, Aurora, Colorado 80045 United States. This is the address for their practice at the University of Colorado Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.